In particular, high levels of VEGF-A and TRF2 expression (VEGF-AH/TRF2H) always correlates with a poor prognosis (Supplementary Fig. S9–10), confirming and reinforcing the predictive relevance of combinatorial analyses based on the evaluation of VEGF-A and TRF2 expression levels in CRC patients, independently from the mutational state of the evaluated driver oncogenes and/or the VEGF-A receptor. The gene discussed is TERF2; the disease is colorectal carcinoma.